Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study to evaluate safety, efficacy, and durability of new enhanced GB-102 formulation in patients with wet Age-related Macular Degeneration (AMD)

Next Previous
Trial Profile

A phase 2 study to evaluate safety, efficacy, and durability of new enhanced GB-102 formulation in patients with wet Age-related Macular Degeneration (AMD)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use

Most Recent Events

  • 20 Mar 2023 According to a CalciMedica media release, GrayBug has merger with CalciMedica and the combined company is named as CalciMedica.
  • 30 Mar 2022 According to a Graybug Vision media release, the company expects to start this study in the fourth quarter of 2022.
  • 14 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top